(Alliance News) - Ondine Biomedical Inc on Monday announced that Steriwave has been used for the first time in an Australian hospital.
The Vancouver-based life sciences company said that Mater Hospital in North Sydney has become the first Australian hospital to start using Steriwave for the prevention of hospital-acquired infections.
Medical Oncologist Frances Boyle said: "We are very pleased to be the first hospital in Australia to have the Steriwave nasal decolonization system. The pathogens patients carry have long been known to cause hospital-acquired infections, especially for the weak and immunocompromised. Having a rapid non-antibiotic approach to decolonizing the nose - a major source of infection transmission - is a benefit to our patients."
Steriwave is a light-activated antimicrobial which employs patented nasal photodisinfection technology to eliminate bacteria, fungi and viruses located on human tissues.
According to Ondine, surgical site infections are "one of the most significant complications in cardiac surgery patients and are strongly associated with poorer prognosis".
This comes after Ondine announced earlier this month that Steriwave had been approved by HCA Healthcare UK for use in its healthcare facilities.
Shares in Ondine were up 3.7% at 7.00 pence each in London on Monday at midday.
By Sabrina Penty, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved.
Ondine Biomed (OBI)